Overview

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Status:
Active, not recruiting

Trial end date:
2024-04-30

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. The Phase III adaptive design allows for the option to recruit up to 584 patients based on pre-specified rules.

Phase:

Phase 3

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Pembrolizumab